PROMISE study: Predicting myeloma risk in high-risk groups
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study uses a blood test to find early signs of myeloma in people at higher risk, such as those with a family history or African ancestry. It aims to predict who might develop myeloma before symptoms appear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 or older and of African American descent or have a first-degree relative with an early blood cancer like MGUS or myeloma
- You are over 18 and have two or more family members with a blood cancer
- You have not been diagnosed with any active cancer or early plasma cell disorder
- You are willing to have your blood tested by mass spectrometry
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This study looks at stored blood (serum) samples to see whether a lab test called MALDI-TOF mass spectrometry can help analyze multiple myeloma proteins. If you have multiple myeloma (or are a healthy matched control), your existing lab samples may be used for testing.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.